Fate Therapeutics (FATE) Operating Leases (2019 - 2026)

Fate Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $72.0 million for Q1 2026.

• Quarterly Operating Leases fell 6.17% year-over-year to $72.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.0 million (down 6.17% YoY) and the FY2025 annual result came in at $73.3 million, down 5.86% from the prior year.
• Operating Leases was $72.0 million for Q1 2026 at Fate Therapeutics, down from $73.3 million in the prior quarter.
• Across five years, Operating Leases topped out at $107.9 million in Q1 2022 and bottomed at $72.0 million in Q1 2026.
• A 5-year average of $91.4 million and a median of $95.7 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases rose 1.34% — and 2024, when it retreated 20.04%.
• Fate Therapeutics' Operating Leases stood at $103.7 million in 2022, then dropped by 6.12% to $97.4 million in 2023, then slipped by 20.04% to $77.8 million in 2024, then dropped by 5.86% to $73.3 million in 2025, then decreased by 1.69% to $72.0 million in 2026.
• Business Quant data shows FATE's Operating Leases at $72.0 million in Q1 2026, $73.3 million in Q4 2025, and $74.5 million in Q3 2025.